The primary objective of this study is to evaluate long-term safety in participants with metastasissolid tumors that are benefitting from continuation with sacituzumab govitecan-hziy.
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
This is a rollover study. Only participants who continue to receive clinical benefit from continuation of sacituzumab govitecan-hziy therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive sacituzumab govitecan-hziy at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.
Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study
Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy
You CAN'T join if...
Females who are pregnant or lactating
Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated
Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy
Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
University of California San Francisco San Francisco California 94143 United States
Rocky Mountain Cancer Center Aurora Colorado 80012 United States